The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress

Oxidative Medicine and Cellular Longevity
Hugo Juárez OlguínGerardo Barragán Mejía

Abstract

Dopamine is a neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dysfunction of the dopamine system has been implicated in different nervous system diseases. The level of dopamine transmission increases in response to any type of reward and by a large number of strongly additive drugs. The role of dopamine dysfunction as a consequence of oxidative stress is involved in health and disease. Introduce new potential targets for the development of therapeutic interventions based on antioxidant compounds. The present review focuses on the therapeutic potential of antioxidant compounds as a coadjuvant treatment to conventional neurological disorders is discussed.

References

Jan 1, 1987·Psychopharmacology·J A LiebermanJ Alvir
Jan 1, 1970·Archiv für Psychiatrie und Nervenkrankheiten·W Birkmayer, W Linauer
Apr 1, 1984·The Biochemical Journal·B Halliwell, J M Gutteridge
Jan 1, 1997·Schizophrenia Bulletin·J W MaasS T Weintraub
Oct 1, 1998·Pharmacopsychiatry·W M Abi-SaabJ H Krystal
Oct 16, 1999·Proceedings of the National Academy of Sciences of the United States of America·M S SzczypkaR D Palmiter
Jun 4, 2002·Nature Reviews. Genetics·Patrícia Beldade, Paul M Brakefield
Feb 7, 2004·Science·Min WangPatricia S Goldman-Rakic
Feb 6, 2007·Nature Neuroscience·Susheel VijayraghavanAmy F T Arnsten
Mar 21, 2007·Trends in Neurosciences·Paolo CalabresiMassimiliano Di Filippo
May 7, 2008·Expert Review of Neurotherapeutics·Patrick B Wood
Dec 2, 2008·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Kanako Satoh, Ryouichi Nonaka
Sep 8, 2009·Advances in Experimental Medicine and Biology·Asheeta A Prasad, R Jeroen Pasterkamp
May 21, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ju ShiKatrin Andreasson
Jun 4, 2011·Synapse·Scott C SteffensenJeffrey G Edwards
Nov 22, 2011·Antioxidants & Redox Signaling·Dong-Hee ChoiYoon-Seong Kim
Dec 30, 2011·Current Drug Targets·Belinda CairnsMidori A Yenari
Jan 10, 2012·Genetic Testing and Molecular Biomarkers·Mehmet GencerMakbule Aydin
Feb 24, 2012·The European Journal of Neuroscience·Claus RiekerJan Rodriguez Parkitna
Mar 10, 2012·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Shu-min LiuFang Lu
Apr 10, 2012·CNS & Neurological Disorders Drug Targets·Marcella RealeAntonia Patruno
Apr 10, 2012·CNS & Neurological Disorders Drug Targets·Shams TabrezMohammad A Kamal
Apr 10, 2012·CNS & Neurological Disorders Drug Targets·Christopher Tolleson, Daniel Claassen
May 2, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Ausaf AhmadGautam Palit
May 23, 2012·Molecular Neurobiology·Jing WuLing-Qiang Zhu
Jun 7, 2012·CNS Drugs·Giovanni ScapagniniGiovannangelo Oriani
Aug 24, 2012·Annals of Neurology·Ju ShiKatrin Andreasson
Sep 6, 2012·International Journal of Molecular Sciences·Hemant KumarDong-Kug Choi
Sep 11, 2012·Brain : a Journal of Neurology·YaJun ZhangCristina M Bäckman
Sep 19, 2012·Journal of Pharmacological Sciences·Naohito TokunagaMasahiro Nomoto
Nov 13, 2012·Biological Psychiatry·Allyson V McCormickBrian C Kraemer
Dec 4, 2012·Journal of Psychiatry & Neuroscience : JPN·Sharon Miksys, Rachel F Tyndale
Dec 19, 2012·Indian Journal of Pharmacology·Bhaveshkumar V AntalaMangala Lahkar

❮ Previous
Next ❯

Citations

May 10, 2020·International Journal of Environmental Research and Public Health·Birgitta Dresp-Langley
Mar 7, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Disha VarijakzhanSwee-Hua Erin Lim
Jun 11, 2020·Mikrochimica Acta·Federica MarianiWolfgang Schuhmann
May 29, 2020·Neurochemical Research·Ashish SinghSarika Singh
Mar 3, 2020·Frontiers in Pharmacology·Vadim V TarasovGjumrakch Aliev
Feb 23, 2020·International Journal of Molecular Sciences·Tatiana V TatarinovaJeffrey Davis
Sep 30, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Sunisha AryalJohn T Weber
Jun 17, 2020·Proteomics. Clinical Applications·Huiyuan ZhaoXiaozhe Zhang
Aug 28, 2020·Frontiers in Integrative Neuroscience·Ankita JenaNicole C Roy
Dec 2, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Luna Rodriguez-SalazarAndrés Cifuentes
Apr 15, 2020·Experimental Neurology·Epiphani C SimmonsRick G Schnellmann
Apr 22, 2021·Neurotoxicology·Yasser A KhadrawyHaitham S Mohammed
May 1, 2021·Journal of the Electrochemical Society·Pauline WonnenbergAlexander G Zestos
May 25, 2021·Frontiers in Neuroscience·Denise Elfriede Liesa Lockhofen, Christoph Mulert
Jul 6, 2021·Journal of Alzheimer's Disease : JAD·David R ElmalehEran Segal
Jul 11, 2021·Molecular Biology Reports·Martyna GachowskaJulita Kulbacka
Aug 15, 2021·Journal of Ethnopharmacology·Emmanuel Ayodeji AyeniXun Liao
Aug 15, 2021·Clinica Chimica Acta; International Journal of Clinical Chemistry·Saad LatifMohammad Azam Ansari
Aug 26, 2021·Molecular Neurobiology·E C D GonçalvesR C Dutra
Aug 24, 2021·Brain Communications·Débora da Luz SchefferAlexandra Latini
Aug 28, 2021·International Journal of Molecular Sciences·Carmen Costas-Ferreira, Lilian R F Faro
Sep 17, 2021·Biomaterials Science·Qingqing FanRona Chandrawati
Nov 24, 2021·Chemical Communications : Chem Comm·Neha ThakurTharamani C Nagaiah
Nov 27, 2021·Molecular Neurobiology·Xin LiYufeng Liu
Nov 30, 2021·Amino Acids·Suzane Rosa da SilvaEduardo R Perez Gonzalez

❮ Previous
Next ❯

Software Mentioned

VMAT

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Autophagy & Aging: Inhibitors

The feed focuses on the role of nuclear export inhibitors and their effect on autophagy and the aging process.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Aphasia

Aphasia affects the ability to process language, including formulation and comprehension of language and speech, as well as the ability to read or write. Here is the latest research on aphasia.